| |
Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3
Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world4-6
IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis |
| |
| |
| |
| 上一篇：Gradiant宣布建成全球首个油田采出水全集成锂生产设施 |
| 下一篇：村田开发面向工业设备的数字三轴MEMS加速度传感器SCA3400系列 - 业内居先，长期使用下传感器输出变化值仍可控制在0.5mg以下 |
| |
| |
| |
